Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...

Simulations Plus has recently declined after its Q3 2025 report, despite having a healthy revenue growth and adjusted EPS beat. This decline was mostly driven by a non‑cash impairment and lowered ...

Simulations Plus (NASDAQ:SLP) reported fiscal first-quarter 2026 results that management said came in line with internal ...

Chemical and biochemical processes can be modeled in silico based on knowledge of the molecular structure of the species involved and understanding basic chemical interactions, allowing such processes ...

AUSTIN, Texas and TOKYO, Nov. 27, 2025 /PRNewswire/ -- According to DataM Intelligence, the In-Silico Clinical Trials Market Size was USD 3.76 billion in 2023, increased to USD 3.95 billion in 2024, ...

MORRISVILLE, N.C. and MILAN and TRIESTE, Italy , March 13, 2023 /PRNewswire/ -- Premier Research, whose mission is to help the most innovative biotech and device companies take their best ideas from ...